Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Reproductive Health
Published in: Reproductive Health 1/2015

Open Access 01-12-2016 | Research

Is protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysis

Authors: Yonatan Moges Mesfin, Kelemu Tilahun Kibret, Amsalu Taye

Published in: Reproductive Health | Issue 1/2015

Login to get access

Abstract

Background

Antiretroviral therapy is recommended during pregnancy to decrease the risk of perinatal transmission of HIV-1 infection and to improve maternal health. However, some studies have reported that antiretroviral treatment (ART) containing protease inhibitors (PI) is associated with an increased risk of preterm birth. In contrast, other studies have reported no increased risk. This meta-analysis was conducted to derive a more reliable estimate of the association between the prenatal use of PI based ART regimen and preterm birth.

Methods

A systemic review and meta-analysis was conducted using published studies which were identified through a computerized search using the Medline/PubMed database, Google Scholar and Health Inter Network Access to Research Initiative (HINARI). The analysis was undertaken using STATA version 11.0 software and studies were described by forest plot. Heterogeneity across studies was checked using Cochran Q test and I2 test. An adjusted odd ratio with 95 % confidence intervals [95 % CI] was pooled using a random effects model.

Results

The Cochrane Q test (Q test p = 0.051) showed a good homogeneity among studies. However, medium heterogeneity was observed in up to 46 % of the sample using the I2 test (I2 = 46.5 %). The Egger weighted regression method (p = 0.04) showed evidence of publication bias, but Begg rank correlation statistics (p = 0.47) did not show evidence of publication bias. The pooled analysis of 10 studies showed that protease based ART exposure during pregnancy was associated with an increased risk of preterm birth (pooled odds ratio 1.32 (95 % CI, 1.04 to 1.59).

Conclusions

This meta-analysis revealed that the PI based ART exposure during pregnancy is significantly associated with an increased risk of preterm birth. There should be strong cautions against initiating ART during pregnancy and PI based ARV should be replaced by others drug regime. Protease inhibitor ART drugs should not be included as part of therapy during pregnancy.
Literature
1.
2.
Copper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of prenatal HIV-1 transition. J Aquir Immune Defic Syndr. 2002;29(5):484–94.CrossRef
3.
Delicio AM, Milanez H, Amaral E, Morais SS, Lajos GJ, PintoeSilva JC, et al. Mother-to-child transmission of human Immune deficiency virus in a ten years period. BMC Reproductive Health 2011; 8(35):doi:10.​1186/​742-4755-8-35.
4.
Senise JF, Castelo A, Martinez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS Rev. 2011;13:198–213.PubMed
5.
Ciaranello AL, Seage GR, Freedberg KA, Weinstein MC, Lockman S, Walensky RP. Antiretroviral drugs for preventing mother-to-child Transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS. 2008;22(17):2359–69.CrossRefPubMedPubMedCentral
6.
Watts D. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med. 2002;346:1879–91.CrossRefPubMed
7.
Ravizza M, Martinelli P, Bucceri A. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis. 2007;195:913–4.CrossRefPubMed
8.
Cotter AM, Garcia AG, Duthely ML, Luke B, O’Sullivan AMJ. Is Antiretroviral Therapy during Pregnancy Associated with an Increased Risk of Preterm Delivery, Low Birth Weight, or Stillbirth? J infec Dis. 2006;193:1195–201.CrossRef
9.
Kourtis A, Schmid C, Jamieson D, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21:607–15.CrossRefPubMed
10.
Alemu FM, Yalew AW, Fantahun M, Ashu EE. Antiretroviral Therapy and Pregnancy Outcomes in Developing Countries: A Systematic Review. Inter Journal of MCH and AIDS. 2015;3(1):31–43.
11.
Grosch-Woerner I, Puch K, Maier R, Niehues T, Notheis G, Patel D, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV 1-infected women. HIV Med. 2008;9:6–13.CrossRefPubMed
12.
Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG. Spectrum of HIV Disease Consortium Declines in Low Birth Weight and Preterm Birth Among Infants Who Were Born to HIV-Infected Women During an Era of Increased Use of Maternal Antiretroviral Drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics. 2007;119(4):e900–6. doi:10.​1542/​peds.​2006-1123.CrossRefPubMed
13.
Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346(24):1863–70.CrossRefPubMed
14.
Szyld EG, Warley EM, Freimanis L, Goninf R, Cahn PE, Calvet GA, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS. 2006;20(8):2345–53.CrossRefPubMed
15.
Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21(8):1019–26.CrossRefPubMed
16.
Hankin C, Thorne C, Peckham C, Newell M-l. European Collaborative Study: Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003;32(4):380–7.CrossRef
17.
Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. AIDS. 1998;12:241–7.CrossRef
18.
Thorne C, Patel D, Newell M, for the European Collaborative Study. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18:2337–9.CrossRefPubMed
19.
Martin F, Taylor G. Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: a single-center cohort study. JID. 2007;196:558–61.CrossRefPubMed
20.
The European Collaborative Study and the Swiss Mother + Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000;14:2913–20.CrossRef
21.
Borenstein M, Hedges L, Higgins J, Rothstein H. Introduction to Meta-Analysis. 1st ed. Chichester: John Wiley & Sons, Ltd; 2009.CrossRef
22.
Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek MAM, Bardeguez AD, et al. Antenatal Protease Inhibitor use and Risk of Preterm Birth among HIV-infected Women Initiating Antiretrovirals during Pregnancy. J Infect Dis. 2010;201(7):1035–44. doi:10.​86/​651232.CrossRefPubMedPubMedCentral
23.
Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, et al. Increased Risk of Preterm Delivery Among HIV Infected Women Randomized to Protease Versus Nucleoside Reverse Transcriptase Inhibitor-Based HAART During Pregnancy. J Infect Dis. 2011;204:506–14.CrossRefPubMedPubMedCentral
24.
Metadata
Title
Is protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysis
Authors
Yonatan Moges Mesfin
Kelemu Tilahun Kibret
Amsalu Taye
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Reproductive Health / Issue 1/2015
Electronic ISSN: 1742-4755
DOI
https://doi.org/10.1186/s12978-016-0149-5

Other articles of this Issue 1/2015

Reproductive Health 1/2015 Go to the issue

Research

Practice and Intention to use long acting and permanent contraceptive methods among married women in Ethiopia: Systematic meta-analysis

Research

Challenges and strategies for sustaining youth-friendly health services — a qualitative study from the perspective of professionals at youth clinics in northern Sweden

Review

Tocolysis for inhibiting preterm birth in extremely preterm birth, multiple gestations and in growth-restricted fetuses: a systematic review and meta-analysis

Editorial

Reproductive Health is pleased to announce a mandatory open data policy in the journal

Research

Preventive induction of labor for non-urgent indications at term and maternal and neonatal outcomes

Research

Graphical displays for effective reporting of evidence quality tables in research syntheses